- Home
- SPMC vs MNMD Comparison
SPMC vs MNMD Comparison
Compare SPMC & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPMC
- MNMD
- Stock Information
- Founded
- SPMC 2022
- MNMD 2019
- Country
- SPMC United States
- MNMD United States
- Employees
- SPMC N/A
- MNMD N/A
- Industry
- SPMC
- MNMD Pharmaceuticals and Biotechnology
- Sector
- SPMC
- MNMD Health Care
- Exchange
- SPMC NYSE
- MNMD Nasdaq
- Market Cap
- SPMC N/A
- MNMD 541.7M
- IPO Year
- SPMC N/A
- MNMD N/A
- Fundamental
- Price
- SPMC $17.72
- MNMD $6.68
- Analyst Decision
- SPMC Strong Buy
- MNMD Strong Buy
- Analyst Count
- SPMC 2
- MNMD 8
- Target Price
- SPMC $21.75
- MNMD $26.29
- AVG Volume (30 Days)
- SPMC 28.5K
- MNMD 1.2M
- Earning Date
- SPMC 08-14-2025
- MNMD 08-12-2025
- Dividend Yield
- SPMC 11.97%
- MNMD N/A
- EPS Growth
- SPMC N/A
- MNMD N/A
- EPS
- SPMC N/A
- MNMD N/A
- Revenue
- SPMC $84,324,319.00
- MNMD N/A
- Revenue This Year
- SPMC $11.51
- MNMD N/A
- Revenue Next Year
- SPMC $10.47
- MNMD N/A
- P/E Ratio
- SPMC $17.11
- MNMD N/A
- Revenue Growth
- SPMC 81.83
- MNMD N/A
- 52 Week Low
- SPMC $16.26
- MNMD $4.70
- 52 Week High
- SPMC $22.30
- MNMD $10.44
- Technical
- Relative Strength Index (RSI)
- SPMC N/A
- MNMD 44.84
- Support Level
- SPMC N/A
- MNMD $6.35
- Resistance Level
- SPMC N/A
- MNMD $7.29
- Average True Range (ATR)
- SPMC 0.00
- MNMD 0.46
- MACD
- SPMC 0.00
- MNMD -0.10
- Stochastic Oscillator
- SPMC 0.00
- MNMD 19.65
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).